Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Market & Technology Analysis (Adsorbi)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: Sweden
Call: Women TechEU (HORIZON-EIE-2022-SCALEUP-02, 2022)
Start date: 2023-07-01
End date: 2024-03-31
Duration (months): 9.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Adsorbi is a deep tech startup company from Gothenburg Sweden and was founded after several years of research within materials chemistry. Adsorbi's innovation is a biobased adsorbent material, which captures harmful pollutants with high capacity. The aim is to replace activated carbon in applications for pollutant removal to lower the high environmental impact and material use of today. The goal of the project is to identify which of the many potential application areas to target, specifically, what should be the first products and who is the ideal first customer of Adsorbi. The project is divided into four objectives: perform a market analysis, perform a technical feasibility study, perform an IP strategy evaluation, and develop a business case around shortlisted attractive application areas.

Keywords: biomaterials,air purification,air pollution cellulose,
Delineating Convergent and Divergent Cortico-Cerebellar pathways in motor Control (CODI-MAP)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing , nervous system  function and dysfunction , systems neuroscience  and modelling , biological basis of cognitive processes and of behaviour, neurological and mental disorders – In humans and all other organisms
Countries involved: Netherlands
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-11-01
End date: 2030-10-31
Duration (months): 60.0
Total project cost (EUR): 2625000.0
EU funding (EUR): 2625000.0
Participants: 1
Project status: SIGNED

The CODI-MAP aims to address a fundamental question: How do the cerebral cortex and cerebellum cooperate to generate and regulate movements? Despite their pivotal contribution to motor control, the complex nature of cortico-cerebellar interaction remains a mystery. Our recent work has demonstrated a significant interdependency between the cortical and cerebellar activities, however the precise architecture and computational strategy that cortico-cerebellar circuits employ to generate and maintain task specific information is unknown. Here, I propose to comprehensively address the detailed reciprocal connectivity of the cortico-cerebellar circuits, their functional interaction during goal directed voluntary movements, as well as their contribution to sensorimotor learning. Our central hypothesis is that the cortico-cerebellar circuits form complex networks characterized by both extensive convergence and divergence. This configuration provides a spectrum of task-related functional modules for sensorimotor control and learning. By engaging specific functional modules, the cortico-cerebellar networks achieve the required spatiotemporal precision for directing movements. We will first systematically dissect the anatomical and molecular features of the cortico-cerebellar pathways using a suite of sophisticated combinatorial viral-genetic strategies. Next, we will identify and manipulate the functional circuits that control forelimb movements using novel multi-regional electrophysiological and optical methods. Finally, we will combine in silico simulation with dual-regional optical recording and manipulation to uncover the plastic changes within cortico-cerebellar circuits during learning. The outcome of this project has the potential to challenge the conventional perspective that considers cortex and cerebellum as distinct computational entities, proposing a multi-regional integrative circuitry, thereby unveiling fundamental principles of how the brain generates action.

Keywords: cortico cerebellar circuits,sensorimotor control,multi regional interaction
Molecular design and application of splice-switching antibody-oligonucleotide conjugate for hypertrophic cardiomyopathy-related MYBPC3 splice modulation. (HCMSpliceAOC)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Portugal,Germany
Call: Fostering balanced brain circulation – ERA Fellowships (HORIZON-WIDERA-2022-TALENTS-04, 2022)
Start date: 2023-06-01
End date: 2025-05-31
Duration (months): 24.0
Total project cost (EUR): 156778.56
EU funding (EUR): 156778.56
Participants: 3
Project status: CLOSED

Familial hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and is predominately caused by mutations in genes that encode proteins associated with cardiac sarcomeres, the functional unit critical for basic contractile heart function. Nearly two-thirds of individuals with HCM experience mild to no symptoms, whereas the remaining one-third experience dyspnea, chest pain, or arrythmias that can progress into heart failure, causing sudden cardiac death, particularly in young competitive athletes. Current strategies to treat HCM include invasive procedures such as septal or left ventricular reduction therapies or cardiac implantation. Such methods are not curative, but rather aimed to treat symptoms and not the pathophysiological cause of the disease, thus highlighting the importance of new molecular therapies that can prevent HCM. One potential method to correct HCM mutations is through the use of antisense oligonucleotides (ASOs), short polymeric nucleic acid biomolecules, that can correct aberrant RNA splicing, a fundamental biological process for gene expression, by binding to pre-mRNA splice sites and block recognition by the spliceosome. However, delivery of ASOs to cardiac cell models, including cardiomyocytes differentiated from human induced pluripotent stem cells (iPSC-CMs), remains to be one of the biggest challenges in ASO efficacy. Herein, this project proposes to design and test the effects of chemically-modified, splice-switching antisense oligonucleotides conjugated to an antibody, an antibody-oligonucleotide conjugate (AOC), using a unique traceless linker strategy that has the potential to not only treat splicing defects in HCM, but also provide proof-of-concept of improved cell delivery of ASOs. AOCs will be tested in iPSC-CMs bearing cryptic splice mutations in MYBPC3 (myosin binding protein C), a gene whose mutations are commonly associated with HCM.

Keywords: antisense oligonucleotides,antibody bioconjugation,rna splicing,cardiomyocytes,cardiomyopathy
Identifying ChloroPlast Ribosome rescue mechanisms under genetically induced and environmental stresses (CPRrescue)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-09-01
End date: 2026-08-31
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 1
Project status: SIGNED

Photosynthesis produces all organic material on Earth. In plants, photosynthesis depends on active protein synthesis in chloroplasts to set up photosynthetic complexes. Due to their endosymbiotic origin (from cyanobacteria), chloroplasts contain an independent genome and internal transcription and translation machinery with bacterial type 70S-like ribosomes. Ribosomes may stall due to transcription errors, misprocessed transcripts, translation mistakes, missing tRNA, mutations, or strong mRNA-folding. Ribosome stalling ties up the translation machinery, it is persistent at trace levels but can be exacerbated by environmental stress. Therefore, ribosome rescue mechanisms have evolved in all life domains to resolve stalled ribosomes. Despite its critical role in maintaining photosynthesis and extensive study in eukaryotes and bacteria, little is known about ribosome rescue mechanisms in chloroplasts. In this project, we will characterise chloroplast rescue factors. First, we will examine ArfB, the only known ribosome rescue mechanism ortholog found in chloroplasts by exposing ArfB knockout mutants to translation-stalling inducing stresses, investigating conserved protein motifs, subcellular localisation and overexpression. Additionally, we will study ribosome-stalling effects on chloroplast translation, photosynthesis and metabolism by genetically modifying the chloroplast translation machinery. Finally, we will directly search for novel ribosome rescue factors by identifying proteins physically engaged with stalled chloroplast ribosomes and evaluating their function. Elucidating chloroplast ribosome rescue mechanisms will improve our understanding of the complete photosynthesis support apparatus and inform future biotechnology and crop improvement. Following this fellowship I will leverage the knowledge, methods and transferable skills I acquire to study chloroplast genetics, translation and nuclear-chloroplast interactions in my future lab.

Keywords: chloroplast,plastid,gene expression,translation,ribosome stalling,ribosome rescue,organelle,photosynthesis
Together maximizing the efficacy of prescription drugs in rheumatoid arthritis (SQUEEZE-UP)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Research and Innovation actions
Countries involved: Austria,Romania
Call: Hop on Facility (HORIZON-WIDERA-2023-ACCESS-06, 2023)
Duration (months): 42.0
Total project cost (EUR): 595312.5
EU funding (EUR): 595312.5
Participants: 2
Project status: SIGNED

The SQUEEZE project aims to improve the treatment and quality of life for patients with rheumatoid arthritis (RA) by maximizing the effectiveness of existing drugs through the use of biomarkers and tailored care. The SQUEEZE project consists of a multidisciplinary team from 9 European countries, including clinicians, healthcare professionals, patient research partners, and scientists. The project's initial findings highlighted the significant differences in the use of disease modifying anti-rheumatic drugs (DMARDs) across European countries, including variations in administration routes, dosages, and accessibility. Such differences often reflect the influence of socio-economic factors, leading to inequalities in treatment standards. We therefore present here SQUEEZE-UP, a proposal that will widen SQUEEZE’s scope by including the expertise of the University of Medicine in Bucharest, Romania. This collaboration will provide insights into the socio-economic context and country-specific strategies for the treatment of RA, and access to patients and clinical cohorts from a distinct socio-economic background. SQUEEZE-UP’s further objectives are to advance the careers of young researchers, enhance the competences and infrastructure of UMFCD, and provide better personalized care tailored to patient needs across Europe. The project will combine large-scale data analysis and prospective studies, and its impact will be seen at the system, organization, and beneficiary levels: increased visibility, economic impact on healthcare systems, access to novel technologies, and positive changes in care models. SQUEEZE-UP will also cover the dissemination, exploitation, and communication of results through various channels, including collaboration with national patient organizations and scientific publications. Overall, SQUEEZE-UP will have a significant impact on the lives of RA patients across Europe and will significantly advance research and innovation in Romania.

Keywords: socio economic impact,social determinants of health,maximizing impact,prescription drugs,rheumatoid arthritis
Hacking Photosynthesis: Biosensors for Herbicides and Beyond (B-FHAB)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany,Italy,United Kingdom
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-07-01
End date: 2024-06-30
Duration (months): 24.0
Total project cost (EUR): 173847.36
EU funding (EUR): 173847.36
Participants: 3
Project status: CLOSED

The introduction of agrochemicals has drastically improved crop yields, largely thanks to the use of herbicides that kill crop competing weeds. Unfortunately, herbicides residues often find their way into our ecosystems, drinking water and food. Current means to monitor herbicide residues utilize expensive, time-consuming methodologies such as liquid chromatography coupled to mass spectroscopy, a technique typically restricted to First world countries and trained users. A biosensor provides a means for rapid, low-cost, sensitive herbicide detection that is widely accessible even in developing countries. I have previously evaluated a biosensing platform using an electrode coated with bacterial reaction centres, but found that it was not sensitive enough to meet EU drinking water standards, was limited to sensing a small class of herbicide residues and was not stable enough under storage for widespread distribution. To tackle the issue of low stability, I implemented a redox polymer transduction matrix, resulting in biosensor stability for hours during operation and months in storage. I then approached the most challenging aspect of boosting biosensor sensitivity by re-designing the biological recognition element itself, using docking simulations to guide enzyme design that resulted in validated improvements in biosensor sensitivity in the lab. This forms the platform for my research within the MSCA Postdoctoral fellowship, wherein I seek to push enzyme-herbicide binding affinities to reach a biosensor sensitivity that meets EU standards, expand the scope of sensing beyond a small class of residues, and sense not just single but multiple herbicide residues on a single test strip. The results of this work will lead to a herbicide biosensor that approaches market viability, and lays the groundwork for a modular biosensing platform that can be extended beyond herbicides, to include biomarkers for monitoring health and detecting disease.

Keywords: computer aided rational design of enzymes
Integrated Anthelmintic-Based control of Taenia solium cysticercosis/taeniasis, Soil-transmitted Helminthiasis and Schistosomiasis: safety, effectiveness and implementation strategies (3SI-CONTROL)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Global Health EDCTP3
Action type: Research and Innovation actions
Partnership: EDCTP3 (JU-JTI)
Countries involved: Belgium,Zambia,Tanzania, United Republic of,Spain,Mozambique
Call: Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa (HORIZON-JU-GH-EDCTP3-2024-01-two-stage, 2024)
Start date: 2025-06-01
End date: 2029-05-31
Duration (months): 48.0
Total project cost (EUR): 5500000.0
EU funding (EUR): 5500000.0
Participants: 7
Project status: SIGNED

Control of soil transmitted helminths (STH) and Schistosomiasis (SCH) has been part of routine programmes for many years, yet, the efficacy and effectiveness of these programmes is challenged by low and failing drug efficacy and growing concerns of anthelmintic resistance, calling for a revision of the MDA-drug strategies. In this regard, the novel fixed-dose co-formulation (FDC) including albendazole and ivermectin has proven to be safe and to overcome most of the challenges in drug efficacy for STH. For T. solium the situation is very different from STH and SCH as currently there are no countries routinely implementing control. 3SI-CONTROL will assess the safety and cost-effectiveness of the FDC co-administration with praziquantel in reducing the prevalence of T. solium, STH and SCH, in a randomised controlled trial embedded in solid implementation research. Results from 3SI-CONTROL will thereby provide a scientific evidence base on the safety and effectiveness of integration of T. solium control with STH and SCH, considering the One Health approach. Beyond this, the substantial implementation research component will enable bridging the gap between the evidence-based practice (results on safety and effectiveness) and the actual implementation in the routine, real-world setting. These results, joined by a comprehensive dissemination and advocacy plan, will provide leverage to stimulate uptake of T. solium in the existing routine NTD control programmes, enabling the implementation of a safe and integrated control strategy with a higher effectiveness, tackling three top ranking NTDs. By harnessing advanced concepts in One Health, implementation research, and pharmacovigilance, our project aims to deliver transformative impacts in NTD control, reducing the individual, social and economic burdens of resource poor rural populations.

Keywords: taenia solium,sth,schistosomiasis,integrated treatment,one health,control
Short-wave infrared photodetectors based on low-cost, environmentally friendly InSb colloidal quantum dots (ECOSWIR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-09-01
End date: 2024-08-31
Duration (months): 24.0
Total project cost (EUR): 181152.96
EU funding (EUR): 181152.96
Participants: 1
Project status: CLOSED

The development of low-cost optoelectronic devices in the short-wave infrared (SWIR, 1-2 um), would open up a huge number of applications, such as 3D and adverse weather imaging, night vision for surveillance and automotive safety, chemical hazard detection, environmental sensing, and biomedical diagnostics etc. leading to a direct and huge impact on quality of life, health, and security, provided that such technologies are available at low cost and high volumes, to serve consumer electronics markets. To address this large consumer market volume the necessity for low-cost, non-toxic, and complementary metal oxide semiconductor (CMOS) compatible SWIR photodetectors is therefore indispensable. To date, the SWIR has been served by costly epitaxial III-V semiconductors, which are not monolithically integrated to silicon (CMOS) electronics, and suffer from high growth cost and low volume manufacturing. Compared to epitaxial technology, solution-processed technology based on colloidal quantum dots (CQDs) is more promising for SWIR photodetectors due to low cost and high volume manufacturing, and their CMOS integrability. On the other hand, InSb is an environmentally friendly III–V semiconductor which possesses a narrow direct band gap and the highest room temperature carrier mobility, and the smallest exciton binding energy of all semiconductors, thus being ideal for SWIR photodetectors. Therefore, ECOSWIR aims to develop a whole new material platform based on non-epitaxial InSb CQDs that, in contrast to current III-V technologies, will enable CMOS compatibility and large-scale production of optoelectronic materials.Utilizing this achievement, ECOSWIR will provide a proof of principle of InSb CQDs SWIR photodetectors with performance that cannot be met by any prior CQDs devices, that will be competitive to the costly epitaxial technology and warrant introduction into high-volume, consumer electronics markets and pave the way towards printable SWIR photodetctors.

Keywords: colloidal quantum dot,short wave infrared,photodetector,environmentally friendly,low cost
Fostering INCLUsive biomeDicine gEps in research and higher education institutions (INCLUDE)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Reforming and enhancing the European R&I System
Theme: Reforming and enhancing the European R&I System
Destination: Reforming and enhancing the European R&I System
Action type: Coordination and support actions
Countries involved: Italy,United Kingdom,Belgium,Romania,Slovakia,Greece,Spain,Lithuania,Portugal,Latvia
Call: Support to the implementation of inclusive gender equality plans (HORIZON-WIDERA-2024-ERA-01, 2024)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 999890.0
EU funding (EUR): 999889.75
Participants: 11
Project status: SIGNED

The BioMedical Research and Innovation (R&I) sector is characterised by specific challenges, emphasising the need for intersectional gender equality interventions with the potential to benefit health and wellbeing in society. The INCLUDE project drives institutional change towards gender equality and inclusiveness by co-designing, implementing, and evaluating innovative measures to advance Gender Equality Plans (GEPs) within seven public BioMedical Research Performing Organisations (RPOs) and one private Research and Technology Organization (RTO) using intersectional and intersectoral approaches. A geographically inclusive consortium covers 2 EU Member States and 6 Widening countries, in Northern, Eastern, Southern, and Western Europe, with more and less advanced policy frameworks. INCLUDE conducts a comprehensive analysis of GEPs and data collection practices already in place, identifying areas for improvement and potential challenges. The analysis, alongside a mapping of good practices and tools, and the identification of the competencies and learning needs of implementing partners, will inform the co-design of inclusive GEP pilot actions to improve intersectional gender equality. Substantial operationalization of intersectionality is enshrined in the consortium composition comprising scholars and activists who possess significant knowledge, expertise, and specialised tools for implementing an intersectional approach. Tailored training programs and collaborative learning initiatives, the establishment of thematic hubs, a mentoring scheme, and study visits will ensure that internal capacities are fostered, and knowledge sharing is promoted. INCLUDE places emphasis on the long-term sustainability of an intersectional approach to GEPs through the elaboration of detailed sustainability plans and the strengthening of partnerships with the local innovation ecosystems, while promoting and multiplying networking efforts through the INCLUDE toolkit, CoP and Manifesto.

Keywords: gender equality intersectionality inclusion gender equality plan gep institutional change biomedical sciences higher education he research innovation randi